IκB/IKK

기타 NF-κB 억제제

아이소폼 선택적 제품

• 주요 억제제
• 억제제 (38)
• 조절제 (2)

Cat.No.	제품명	정보	제품 사용 인용	제품 검증
S8922	TBK1/IKKε-IN-5	TBK1/IKKε-IN-5 (화합물 1)은 TANK-binding kinase 1 (TBK1) 및 IκB kinase-ε (IKKε/IKK-i)의 이중 억제제로, TBK1 및 IKKε에 대한 IC50 값은 각각 1.0 nM 및 5.6 nM입니다. TBK1/IKKε 억제는 PD-1 차단에 대한 반응을 향상시키며, 이는 생체 내(in vivo) 종양 반응을 효과적으로 예측합니다.	Autophagy, 2025, 1-23. Cancer Res, 2025, 10.1158/0008-5472.CAN-25-1791 Cancer Research, 2025, 12-21
S9042	Wedelolactone	의약용 식물 유래 천연 화합물인 Wedelolactone은 IκBα의 인산화 및 분해를 매개하여 NF-κB를 활성화하는 데 결정적인 역할을 하는 IKK의 억제제입니다. 이 화합물은 또한 caspase-11의 억제제이기도 합니다.	Int J Ophthalmol, 2024, 17(4):616-624 PeerJ, 2022, 10:e13766 Exp Eye Res, 2021, 211:108750
S8078	Bardoxolone Methyl (RTA 402)	Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me)은 IKK 억제제로서 강력한 세포사멸 촉진 및 항염증 활성을 나타내며, 강력한 Nrf2 활성제이자 NF-κB 억제제이기도 합니다. Bardoxolone Methyl은 Ferroptosis를 제거합니다. Bardoxolone methyl은 암세포에서 Apoptosis related 및 Autophagy를 유도합니다.	J Clin Invest, 2025, 135(14)e176655 Redox Biol, 2025, 87:103885 Research (Wash D C), 2025, 8:0980
S1396	Resveratrol (trans-Resveratrol)	Resveratrol (trans-Resveratrol)은 COX(IC50=1.1 μM), Lipoxygenase(IC50=2.7 μM), 키나아제, Sirtuin 및 기타 단백질을 포함한 광범위한 표적을 가지고 있습니다. 이는 항암, 항염증, 혈당 강하 및 기타 유익한 심혈관 효과를 나타냅니다. Resveratrol (trans-Resveratrol)은 Mitophagy/Autophagy 및 Autophagy 관련 Apoptosis related를 유도합니다.	PLoS One, 2026 Mar 16, e0344872 PLoS One, 2026 Mar 16, e0344872 Theranostics, 2026, 16(9):4768-4786
S2882	IKK-16	IKK-16은 무세포 분석에서 IKK-2, IKK complex 및 IKK-1에 대해 각각 40 nM, 70 nM 및 200 nM의 IC50을 나타내는 선택적 IκB kinase (IKK) 억제제입니다. 또한 IKK-16은 세포 내 LRRK2 Ser935 인산화와 50 nM의 IC50으로 시험관 내 LRRK2 키나아제 활성을 억제합니다.	Ann Rheum Dis, 2025, S0003-4967(25)04453-X Nucleic Acids Res, 2025, 53(17)gkaf891 Cell Commun Signal, 2025, 23(1):274
S2824	TPCA-1	TPCA-1 (GW683965)은 세포 무함유 분석에서 17.9 nM의 IC50을 가지는 IKK-2의 억제제이며, NF-κB 경로를 억제하고 IKK-1보다 22배 높은 선택성을 나타냅니다. TPCA-1은 또한 STAT3의 억제제이며 Apoptosis related를 강화합니다.	Nat Genet, 2025, 10.1038/s41588-025-02221-2 EMBO J, 2025, 10.1038/s44318-025-00412-5 EMBO J, 2025, 10.1038/s44318-025-00561-7
S8044	BMS-345541	BMS-345541은 세포 무함유 분석에서 각각 0.3 μM 및 4 μM의 IC50으로 IKK-2 및 IKK-1의 촉매 하위 단위에 대해 매우 선택적인 억제제입니다.	Cell Death Dis, 2025, 16(1):124 Mol Med, 2025, 31(1):197 Cancer Med, 2025, 14(5):e70047
S7352	Bay 11-7085	Bay 11-7085 (Bay 11-7083)은 10 μM의 IC50을 가진 TNFα 유도 IκBα 인산화의 비가역적 억제제입니다.	JCI Insight, 2025, e186456 J Am Soc Nephrol, 2024, 35(8):998-1015 Theranostics, 2024, 861-878
S2864	IMD 0354	IMD-0354(IKK2 Inhibitor V)는 IKKβ 억제제이며 NF-κB 경로에서 IκB/IKK 인산화를 차단합니다.	Hematol Rep, 2026, 18(2)25 Nat Commun, 2025, 16(1):5387 Iran J Basic Med Sci, 2023, 26(8):912-918
S7948	MRT67307 HCl	MRT67307 HCl은 각각 160 및 19 nM의 IC50 값을 갖는 강력한 IKKϵ 및 TBK1 이중 억제제입니다. MRT67307 HCl은 ULK1 및 ULK2를 강력하게 억제하며 Autophagy를 차단합니다.	EMBO Rep, 2025, 10.1038/s44319-025-00444-2 EMBO J, 2024, 10.1038/s44318-024-00244-9 mBio, 2023, 10.1128/mbio.02506-23
1 2

IκB (Inhibitor of κB) functions as a primary inhibitor of NF-κB activation, with an N-terminal regulatory domain, followed by six or more ankyrin repeats and a PEST domain near their C terminus. ^[1] IκB family contains eight known members, IκBα, IκBβ, IκBε, Bcl-3 (B-cell lymphoma 3), IκBζ, and IκBns (NF-κBδ), as well as the precursor Rel proteins p100 (NF-κB2) and p105 (NF-κB1) due to the presence of multiple ankyrin repeats in their C-terminal halves. IκBα and IκBβ are broadly expressed in all type of cells, whereas IκBε is expressed only in hematopoietic cells. Bcl-3, IκBζ and IkBNS are atypical IκB proteins that exhibit limited expression following NF-κB activation. The regulation of IκB proteins varies by protein type, and each IκB moiety exhibits a unique affinity for NF-κB complexes. ^[2]

In unstimulated cells, the IκBα proteins mask the nuclear localization signals (NLS) of NF-κB proteins, keeping them sequestered in an inactive state in the cytoplasm. In response to stimuli, IκB kinase (IKK) phosphorylates IκBα leading to the degradation of IκBα, and subsequent NF-κB activation. IκBα expression can be activated by NF-κB to generate a negative feedback loop. Similar to IκBα, IκBβ acts by sequestering p65- and c-Rel-containing complexes in the cytoplasm. However, nuclear localized IκBβ also binds to p65:c-Rel heterodimers, promoting continued binding to specific κB sites, and augmenting late transcription of select target genes (i.e. TNF and IL-1β). IκBε is induced slowly, and selectively regulates p65 homodimers and c-Rel:p65 heterodimers. Bcl-3 functions as a transcriptional co-activator that may both inhibit and facilitate NF-κB-dependent transcription in a context-specific manner. Like Bcl-3, IκBζ can enhance transcription in association with p50 NF-κB dimmers despite the prescence of distinct mechanisms. IκBns selectively inhibits NF-κB-dependent pro-inflammatory gene expression by stabilizing p50 homodimers at κB sites. In addition to exclusively stabilizing RelB dimers, p100 itself can act more broadly in inhibiting NF-κB dimers. The p105 also acts like a typical IκB protein, and is additionally associated with the activation of the MAPK-ERK signaling pathway through the binding of MAP3K8 (TPL2). Moreover, the functions of individual IκB family members are quite heterogeneous and are not limited to this particular role in regulating NF-κB signaling. ^[2]

In oncology, the direct activation of NF-κB complexes through the loss of the inhibitory proteins IκBα and IκBε has been observed in Hodgkin’s lymphoma. Since the NF-κB signal pathway plays a critical role in tumorigenesis bv way of abberant IκB activity, a variety of compounds targeting IKK and its associated enzymes are in clinical development. ^[3] For instance, the proteasome inhibitor Bortezomib (Velcade®) has been approved by the FDA for use in haematological malignancies. ^[4] In addition, Bortezomib is currently being explored in clinical development for its efficacy against solid tumors (clinicaltrials.gov; NCT00479128).